There’s an article on Piramal’s Pharma Solutions division at PharmTech about how they are encouraging pharma companies to implement green chemistry earlier in the drug development cycle. Yes, we agree…
A genotoxic impurity (GTI) is a chemical substance that can directly or indirectly damage DNA or chromosomes and induce genetic mutations. Fifteen years ago, there were no specific guidelines for…
In what can best be described as a quality paradox, continuous process improvement has become something of a buzzword in the pharma manufacturing industry. But, as Epcot President & CPhI…
It’s a common misconception that process chemistry refers strictly to process scale-up. While it’s true that process chemistry is a crucial component of optimizing the scale up of an active…
Big Data Brings Insights…and Complexities I recently read an interesting article at ContractPharma.com on pharma companies leveraging Big Data to improve their contracting strategies. Our collective ability to identify, capture,…
The continued growth of virtual pharma – and the subsequent rise of virtual biotech – have made a lasting impression on the pharmaceutical contract manufacturing industry. Big Pharma firms, some…
‘One hundred percent purity’ is the holy grail of pharma – and, more generally, the scientific community. Firms in our industry all around the globe spend the overwhelming majority of…
7 ways to boost profits and reduce pharma synthesis waste At Neuland, we’re advocates of green chemistry. Not only is it better for the environment, but it’s also just logistically…
Neuland’s Technology Transfer team wrote a piece that was published back in 2011 in Pharmaceutical Technology on the topic of pharma manufacturing and energy efficiency. Since its publication, the issue…
There have been a number of articles recently pointing to growth in the API industry, and it’s something I’ve discussed as well – most recently in a post on the…
